Vertex Pharmaceuticals (VRTX) Analysts See $0.68 EPS; Orbis Investment Management Has Cut By $385,480 Its Abbvie (ABBV) Position

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Orbis Investment Management decreased Abbvie Inc (ABBV) stake by 2.9% reported in 2018Q4 SEC filing. Orbis Investment Management sold 4,190 shares as Abbvie Inc (ABBV)’s stock declined 10.66%. The Orbis Investment Management holds 140,412 shares with $12.95M value, down from 144,602 last quarter. Abbvie Inc now has $119.81 billion valuation. The stock increased 0.33% or $0.27 during the last trading session, reaching $81.05. About 686,571 shares traded. AbbVie Inc. (NYSE:ABBV) has declined 30.20% since April 15, 2018 and is downtrending. It has underperformed by 34.57% the S&P500. Some Historical ABBV News: 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN; 01/05/2018 – AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab; 13/03/2018 – ABBVIE REPORTS POSITIVE TOPLINE RESULTS FROM SECOND PHASE 3; 26/04/2018 – ABBVIE INC – QTRLY GAAP SHR $1.74; QTRLY ADJ. SHR $1.87; QTRLY WORLDWIDE NET REVENUE $7.93 BLN, UP 21.4 PCT ON GAAP BASIS; 10/04/2018 – AbbVie: Regulatory Submissions for Elagolix in Uterine Fibroids Remain on Track; 24/04/2018 – AstraZeneca: Combination of Imfinzi Plus Tremelimumab Didn’t Meet Primary Endpoints; 13/04/2018 – AbbVie’s Humira Retail Sales Rose 0.4% in Latest Week: Symphony; 13/03/2018 – AbbVie sweeps back-to-back PhIIIs for uterine fibroid patients, adding to elagolix’s blockbuster rep; 07/03/2018 – INVENTIVA SA IVAA.PA – PARTNERSHIP WITH ABBVIE AND BOEHRINGER INGELHEIM IS ADVANCING ON SCHEDULE; 22/03/2018 – BerGenBio ASA: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.68 EPS on April, 25.They anticipate $0.14 EPS change or 25.93% from last quarter’s $0.54 EPS. VRTX’s profit would be $173.85M giving it 66.74 P/E if the $0.68 EPS is correct. After having $1.00 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see -32.00% EPS growth. The stock decreased 0.69% or $1.26 during the last trading session, reaching $181.52. About 127,632 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 14.60% since April 15, 2018 and is uptrending. It has outperformed by 10.23% the S&P500. Some Historical VRTX News: 30/05/2018 – CRISPR, VERTEX PROVIDE UPDATE ON FDA REVIEW OF CTX001 NDA; 20/04/2018 – L3 Vertex bidders submit refresh bids; 04/05/2018 – Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’; 19/03/2018 – VERTEX RESOURCE GROUP – ANTICIPATES PRICING AND MARGIN OF ITS SERVICES TO IMPROVE SLIGHTLY IN 2018; 24/04/2018 – Vertex Announces Partnership and Integration with SAP® Ariba® to Support Global Tax Functionality; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 03/04/2018 – Vertex Tech Promises Joy of Fast Flight – Metres Above Sea; 26/04/2018 – VERTEX PHARMACEUTICALS INC – COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BLN TO $2.80 BLN; 20/03/2018 – L-3’s Vertex draws Platinum Equity, Veritas; 01/05/2018 – L3 SIGNS PACT TO SELL VERTEX AEROSPACE TO AMERICAN INDUSTRIAL P

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Seekingalpha.com which released: “March Outlook For Vertex Pharmaceuticals VRTX – Seeking Alpha” on March 27, 2019, also Nasdaq.com with their article: “First Week of VRTX October 18th Options Trading – Nasdaq” published on March 21, 2019, Nasdaq.com published: “CELG or VRTX: Which Is the Better Value Stock Right Now? – Nasdaq” on March 29, 2019. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Nasdaq.com and their article: “May 3rd Options Now Available For Vertex Pharmaceuticals (VRTX) – Nasdaq” published on March 25, 2019 as well as Nasdaq.com‘s news article titled: “Check Out These 7 Fast-Growing Stocks to Buy Today – Nasdaq” with publication date: April 05, 2019.

Investors sentiment decreased to 0.89 in Q4 2018. Its down 0.17, from 1.06 in 2018Q3. It dropped, as 51 investors sold Vertex Pharmaceuticals Incorporated shares while 205 reduced holdings. 64 funds opened positions while 164 raised stakes. 239.68 million shares or 3.46% more from 231.66 million shares in 2018Q3 were reported. Sg Americas Limited Liability holds 1,939 shares or 0% of its portfolio. Tiaa Cref Invest Mgmt Lc reported 993,287 shares. Csat Inv Advisory Lp has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Everence Management holds 0.23% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 5,884 shares. Central Fincl Bank And Trust invested in 24 shares. Wilbanks Smith And Thomas Asset Mngmt Ltd Liability has invested 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Guardian Tru has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 10 shares. Fmr Limited Liability Corp has 20.48M shares for 0.46% of their portfolio. Edgewood Mgmt Lc reported 35,000 shares. Hwg Hldgs Lp stated it has 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Amer Natl Tx reported 28,025 shares. Essex Inv Mgmt has invested 1.27% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hanson Mcclain reported 26 shares stake. Victory Capital owns 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 3,769 shares. Bancorp Of Montreal Can holds 0.04% or 286,725 shares.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $46.41 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 22.44 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Among 10 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Vertex Pharmaceuticals had 23 analyst reports since October 25, 2018 according to SRatingsIntel. The stock has “Market Perform” rating by Raymond James on Wednesday, January 2. The firm has “Buy” rating by Oppenheimer given on Wednesday, March 6. Cowen & Co maintained the stock with “Buy” rating in Wednesday, March 6 report. As per Wednesday, November 28, the company rating was maintained by H.C. Wainwright. BMO Capital Markets maintained the shares of VRTX in report on Thursday, October 25 with “Outperform” rating. As per Thursday, March 7, the company rating was maintained by H.C. Wainwright. Citigroup maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, January 4 with “Buy” rating. Raymond James maintained it with “Outperform” rating and $201 target in Thursday, October 25 report. The stock has “Neutral” rating by Guggenheim on Tuesday, December 18. The stock has “Overweight” rating by Morgan Stanley on Wednesday, December 19.

Since November 2, 2018, it had 0 buys, and 30 sales for $54.81 million activity. 12,722 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $2.38M were sold by Sachdev Amit. $396,759 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Parini Michael on Monday, January 14. 12 shares were sold by Silva Paul M, worth $1,965 on Thursday, November 15. Arbuckle Stuart A sold 29 shares worth $4,749. $238,020 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by ALTSHULER DAVID. LEIDEN JEFFREY M sold $20.08 million worth of stock.

Among 5 analysts covering AbbVie (NYSE:ABBV), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. AbbVie had 8 analyst reports since November 5, 2018 according to SRatingsIntel. The firm has “Neutral” rating by Bank of America given on Thursday, January 3. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Tuesday, November 6 by Argus Research. UBS reinitiated the stock with “Neutral” rating in Wednesday, January 23 report. BMO Capital Markets maintained the stock with “Underperform” rating in Monday, November 5 report. The firm earned “Hold” rating on Thursday, February 21 by Piper Jaffray. The rating was maintained by Piper Jaffray with “Hold” on Wednesday, March 13.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 25. They expect $2.05 earnings per share, up 9.63% or $0.18 from last year’s $1.87 per share. ABBV’s profit will be $3.03B for 9.88 P/E if the $2.05 EPS becomes a reality. After $1.90 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 7.89% EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “What Investors Are Missing About AbbVie – Seeking Alpha” on March 20, 2019, also Seekingalpha.com with their article: “AbbVie: This 5% Yielding Dividend Aristocrat Is Undervalued – Seeking Alpha” published on April 10, 2019, Seekingalpha.com published: “5 Reasons AbbVie Is My Biggest Holding – Seeking Alpha” on March 18, 2019. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Alder poaches AbbVie exec for top commercial job – Seeking Alpha” published on April 08, 2019 as well as Seekingalpha.com‘s news article titled: “AbbVie’s SKYRIZI OK’d in Japan – Seeking Alpha” with publication date: March 26, 2019.

Since November 29, 2018, it had 0 insider purchases, and 5 insider sales for $21.78 million activity. On Tuesday, December 4 Schumacher Laura J sold $8.81 million worth of AbbVie Inc. (NYSE:ABBV) or 94,140 shares. GONZALEZ RICHARD A also sold $1.50 million worth of AbbVie Inc. (NYSE:ABBV) on Tuesday, December 11. CHASE WILLIAM J sold $5.40M worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, December 12. $3.82M worth of AbbVie Inc. (NYSE:ABBV) shares were sold by Gosebruch Henry O.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart